Samantha Vieira
Director de Operaciones en Anjarium Biosciences AG .
Perfil
Samantha Vieira is currently the Chief Operating Officer at Anjarium Biosciences AG since 2022.
Prior to this, she worked as the Executive Director-Global Product Development at Biogen, Inc. from 2019 to 2021.
Cargos activos de Samantha Vieira
Empresas | Cargo | Inicio |
---|---|---|
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Director de Operaciones | 12/07/2022 |
Antiguos cargos conocidos de Samantha Vieira.
Empresas | Cargo | Fin |
---|---|---|
BIOGEN INC. | Corporate Officer/Principal | 01/08/2021 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
BIOGEN INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Health Technology |
- Bolsa de valores
- Insiders
- Samantha Vieira